Provided by Tiger Trade Technology Pte. Ltd.

SIHUAN PHARM

0.750
-0.030-3.85%
Volume:80.12M
Turnover:60.29M
Market Cap:6.84B
PE:32.64
High:0.775
Open:0.775
Low:0.740
Close:0.780
52wk High:1.896
52wk Low:0.740
Shares:9.12B
HK Float Shares:9.12B
Volume Ratio:1.11
T/O Rate:0.88%
Dividend:0.02
Dividend Rate:2.91%
EPS(LYR):0.023
ROE:5.57%
ROA:2.73%
PB:0.95
PE(LYR):32.64
PS:2.23

Loading ...

Sihuan Pharma signs strategic R&D collaboration with Biocytogen on AI antibody platform

Reuters
·
Apr 01

Sihuan Pharma - First Project Focuses on Next-Generation Weight Loss Drug

THOMSON REUTERS
·
Apr 01

Sihuan Pharma: March 2026 Share Capital Stable, No New Issuances or Treasury Movements

Bulletin Express
·
Apr 01

Sihuan Pharmaceutical Declares RMB 0.0096 Final Dividend for FY 2025

Bulletin Express
·
Mar 31

Sihuan Pharmaceutical Returns to Profitability with FY Net Income of 180 Million Yuan

Stock News
·
Mar 31

Sihuan Pharmaceutical 2025 Results: Revenue Climbs 37.7%, Turns Profitable on Medical Aesthetics Surge

Bulletin Express
·
Mar 31

Sihuan Pharma FY25 revenue climbs 37.7% to RMB 2.6 billion

Reuters
·
Mar 31

Sihuan Pharma - FY Profit Attributable RMB179.7 Mln

THOMSON REUTERS
·
Mar 31

Sihuan Pharma - Final Cash Dividend of RMB0.96 Cents per Share

THOMSON REUTERS
·
Mar 31

Xuanzhu Biopharma FY25 loss narrows 55.9% to RMB 250 million

Reuters
·
Mar 30

Sihuan Pharmaceutical unit publishes BRIGHT-2 Phase 3 results for biloxcilib plus fulvestrant in JAMA Oncology

Reuters
·
Mar 24

Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer

Reuters
·
Mar 24

Xuanzhu Biopharmaceutical completes enrollment of 500 patients in China Phase 3 trial of anaprazole sodium enteric-coated tablets for reflux esophagitis

Reuters
·
Mar 22

Xuanzhu Biopharmaceutical completes enrollment of 500 subjects in China Phase III reflux esophagitis trial of anaprazole sodium tablets

Reuters
·
Mar 22

Sihuan Pharma (00460) Schedules 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend

Bulletin Express
·
Mar 19

Assessing Sihuan Pharmaceutical Holdings Group’s Valuation After Bireociclib’s New First Line Breast Cancer Approval

Simply Wall St.
·
Mar 11

Sihuan Pharmaceutical affiliate Xuanzhu Biopharm enters Hong Kong Stock Connect list

Reuters
·
Mar 08

SIHUAN PHARM (00460) Rises Over 5% in Morning Session as Xuan Yue Ning® Gains Third Indication Approval from NMPA

Stock News
·
Mar 05